US7514550B2
Active / In Force
US
⏱️ 0.9 years remaining
siRNA targeting myeloid cell leukemia sequence 1
Assignee: Thermo Fisher Scientific Inc
•
Filing: 2007-09-20
•
Granted: 2009-04-07
•
Expires: 2027-09-20
Abstract
Abstract Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Inventors
- 👤 Anastasia Khvorova
- 👤 Angela Reynolds
- 👤 Devin Leake
- 👤 William Marshall
- 👤 Stephen Scaringe
- 👤 Steven Read
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 05:08
CPC Classifications
C; C12; C12Y; C12Y113/00; C12Y113/12; C12Y113/12007; A; A61; A61K; A61K31/00; A61K31/70; A61K31/7088; A61K31/713; A61P; A61P13/00; A61P13/12; A61P21/00; A61P25/00; A61P25/28; A61P3/00; A61P3/08; A61P3/10; A61P35/00; A61P35/02; A61P37/00; A61P37/02; C12N; C12N15/00; C12N15/09; C12N15/10; C12N15/1034; C12N15/1048; C12N15/11; C12N15/111; C12N15/113; C12N15/1135; C12N15/1136; C12N15/1137; C12N15/1138; C12Y502/00; C12Y502/01; C12Y502/01008; G; G16; G16B; G16B20/00; G16B20/20; G16B20/50; C12N2310/00; C12N2310/10; C12N2310/14; C12N2320/00; C12N2320/10; C12N2320/11
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
70 words
An siRNA molecule consisting of: (a) a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region consisting of 19-30 base pairs and said antisense region comprises a sequence that is the complement of SEQ ID NO 461; and (b) either zero overhang regions, or one or more overhang regions, wherein each overhang region is six or fewer nucleotides in length.
Claim 2
Dependent Claim
70 words
An siRNA molecule consisting of: (a) a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region consisting of 19-30 base pairs and said antisense region comprises a sequence that is the complement of SEQ ID NO 461; and (b) either zero overhang regions, or one or more overhang regions, wherein each overhang region is six or fewer nucleotides in length.
Claim 3
Dependent Claim
21 words
The siRNA molecule of claim 1 , wherein said antisense region and said sense region are each 19-25 nucleotides in length.
Claim 4
Dependent Claim
21 words
The siRNA molecule of claim 2 , wherein said antisense region and said sense region are each 19 nucleotides in length.
Claim 5
Dependent Claim
21 words
The siRNA molecule of claim 1 , wherein said antisense region is 100% complementary to a region of a target mRNA.
Claim 6
Dependent Claim
17 words
The siRNA molecule of claim 1 , wherein said siRNA molecule has at least one overhang region.
Claim 7
Dependent Claim
16 words
The siRNA molecule of claim 1 , wherein said siRNA molecule has only one overhang region.
Claim 8
Dependent Claim
15 words
The siRNA molecule of claim 1 , wherein said siRNA molecule has two overhang regions.
Claim 9
Dependent Claim
15 words
The siRNA molecule of claim 1 , wherein said siRNA molecule has no overhang regions.
Claim 10
Dependent Claim
17 words
The siRNA molecule of claim 2 , wherein said siRNA molecule has at least one overhang region.
Claim 11
Dependent Claim
15 words
The siRNA molecule of claim 2 , wherein said siRNA molecule has no overhang regions.
Claim 12
Dependent Claim
17 words
The siRNA molecule of claim 3 , wherein said siRNA molecule has at least one overhang region.
Claim 13
Dependent Claim
15 words
The siRNA molecule of claim 3 , wherein said siRNA molecule has no overhang regions.
Claim 14
Dependent Claim
56 words
A chemically synthesized double stranded siRNA molecule that directs cleavage of an mRNA via RNA interference, wherein: a. each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length; and b. one strand of said double stranded siRNA molecule comprises a sequence that is the complement of SEQ ID NO 461.
Claim 15
Dependent Claim
56 words
A chemically synthesized double stranded siRNA molecule that directs cleavage of an mRNA via RNA interference, wherein: a. each strand of said double stranded siRNA molecule is between 19 and 30 nucleotides in length; and b. one strand of said double stranded siRNA molecule comprises a sequence that is the complement of SEQ ID NO 461.
Claim 16
Dependent Claim
25 words
The chemically synthesized double stranded siRNA molecule of claim 13 , wherein each strand of said double stranded siRNA molecule is 19 nucleotides in length.
Claim 17
Dependent Claim
71 words
An siRNA molecule, wherein said siRNA molecule consists of: (a) a sense region, wherein said sense region consists of a sequence that is SEQ ID NO 461, and an antisense region, wherein said antisense region consists of a sequence that is the complement of SEQ ID NO 461; and (b) either zero overhang regions, or one or more overhang regions, wherein each overhang region is six or fewer nucleotides in length.
Claim 18
Dependent Claim
71 words
An siRNA molecule, wherein said siRNA molecule consists of: (a) a sense region, wherein said sense region consists of a sequence that is SEQ ID NO 461, and an antisense region, wherein said antisense region consists of a sequence that is the complement of SEQ ID NO 461; and (b) either zero overhang regions, or one or more overhang regions, wherein each overhang region is six or fewer nucleotides in length.
Claim 19
Dependent Claim
15 words
The siRNA molecule of claim 15 , wherein said siRNA molecule has no overhang regions.
Claim 20
Dependent Claim
15 words
The siRNA molecule of claim 16 , wherein said siRNA molecule has one overhang region.
Claim 21
Dependent Claim
15 words
The siRNA molecule of claim 17 , wherein said siRNA molecule has two overhang regions.
References Cited (Backward Citations)
US20020086321A1
Cited
US20040204380A1
Cited
US20040259247A1
Cited
US20050176025A1
Cited
US20040101915A1
Cited
US20070254850A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2012-04-06 | 2012-10-06 | 2013-04-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2016-04-06 | 2016-10-06 | 2017-04-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2020-04-06 | 2020-10-06 | 2021-04-07 | $7700.00 | Window Closed / Lapsed |